[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","qdockbcooa4g9x5k5v8ii8tw6","revision",2,"title","Ocular Therapeutix 公司高管离职公告","originalTitle","OCULAR THERAPEUTIX, INC (0001393434) (Filer)","summary","Ocular Therapeutix 首席战略官 Sanjay Nayak 于 2026 年 10 月 16 日离职，将出任另一家私营公司 CEO。公司已按要求提交 8-K 报告。","reason","source",{"_11":87,"_88":89,"_90":91,"_92":57,"_93":94,"_95":96},"links",{"_84":85,"_63":86},"publishedAt","2026-10-16T20:15:32.000Z","discoveredAt","2026-10-16T23:52:08.077Z","timelineAt","category","ai-products","tags",[81,82,83],"stockSymbols",[80],"score",30,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","f5IgVxn04oKo",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","b28b8bc5-9718-416b-82d5-7f41837400f3","Ocular Therapeutix 首席战略官离职",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):\nOctober 14, 2026

OCULAR\nTHERAPEUTIX, INC.

(Exact Name of Registrant as Specified in its\nCharter)

\n\n \n \n \n \n \n\n \n \n \n \n \n

Delaware		001-36554		20-5560161
(State or Other Jurisdiction\n \n of Incorporation)		(Commission \n File Number)		(IRS Employer \n Identification No.)

14\nCrosby Drive, 3rd Floor

Bedford,\nMA 01730

(Address of Principal Executive Offices) (Zip\nCode)

Registrant’s telephone number, including area\ncode: (781) 357-4000

Check the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

\n\n \n \n

¨	Written communications\n pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

\n\n \n \n

¨	Soliciting\n material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

\n\n \n \n

¨	Pre-commencement\n communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

\n\n \n \n

¨	Pre-commencement\n communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

\n\n \n \n \n \n \n\n \n \n \n \n \n

Title of each class		Trading Symbol(s)		Name of\n each exchange on which \n registered
Common\n Stock, $0.0001 par value per share		OCUL		The\n Nasdaq Global Market

Indicate by check mark whether\nthe registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)\nor Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company,\nindicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised\nfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure\nof Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 14, 2026, Sanjay Nayak, M.B.B.S., Ph.D.,\nChief Strategy Officer of Ocular Therapeutix, Inc. (the “Company”), notified the Company of his resignation from the Company,\neffective October 16, 2026, to become the Chief Executive Officer of a privately-held company.

SIGNATURES

Pursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	OCULAR THERAPEUTIX, INC.

Date: October 16, 2026	By:	/s/ Jason S. Robins
		\n Jason S. Robins \n Chief Financial Officer

","zhKind","complete","OCUL","政策与监管","退市","公司与财报","aihot","/items/qdockbcooa4g9x5k5v8ii8tw6","https://www.sec.gov/Archives/edgar/data/1393434/000110465926116617/0001104659-26-116617-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792454400&sig=3dbe6cd67490ee5b","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792454400&sig=28d09d2ec91c5a63 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792454400&sig=4324ec5a457d0f39 96w","changelogVersion","2026-10-01T08:00"]